Trial Outcomes & Findings for Ageing and Health. Spanish Longitudinal Study (NCT NCT03343886)
NCT ID: NCT03343886
Last Updated: 2024-10-15
Results Overview
Measure: Health composite total score. Construct: Health status. Final result: A global total score. Range: 0-100. 0 means lower health status.
ACTIVE_NOT_RECRUITING
7755 participants
Baseline
2024-10-15
Participant Flow
Spanish general adult population non-institutionalized; aged 18+ years with oversampling of those aged 50+ years and those 80+ years); multi-stage stratified sampling; representative sample.
Respondents unable to undertake the interview because of severe cognitive or physical impairment were administered a shorter version of the questionnaire to a proxy respondent.
Participant milestones
| Measure |
Cohort 2011
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Overall Study
STARTED
|
4753
|
3002
|
|
Overall Study
Second Wave
|
2528
|
0
|
|
Overall Study
Third Wave
|
1577
|
0
|
|
Overall Study
Fourth Wave
|
963
|
0
|
|
Overall Study
COMPLETED
|
963
|
0
|
|
Overall Study
NOT COMPLETED
|
3790
|
3002
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Ageing and Health. Spanish Longitudinal Study
Baseline characteristics by cohort
| Measure |
Cohort 2011 Sample Demographic Characteristics
n=4 Participants
The 2011 Cohort is part of a nationally representative sample of the Spanish noninstitutionalized adult population. Potential respondents were selected by a stratified, multistage, clustered area probability design, without replacement, according to the Spanish regions and population size.
|
Cohort 2019 Sample Demographic Characteristics
n=3002 Participants
In 2019-2021 3,002 participants were brought in (2019 cohort), using the same sample characteristics .
|
Total
n=7755 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=4753 Participants
|
0 Participants
n=3002 Participants
|
0 Participants
n=7755 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
2742 Participants
n=4753 Participants
|
1,867 Participants
n=3002 Participants
|
4609 Participants
n=7755 Participants
|
|
Age, Categorical
>=65 years
|
2011 Participants
n=4753 Participants
|
1,135 Participants
n=3002 Participants
|
3146 Participants
n=7755 Participants
|
|
Age, Continuous
|
60.44 years
STANDARD_DEVIATION 16.24 • n=4753 Participants
|
58.19 years
STANDARD_DEVIATION 17.89 • n=3002 Participants
|
59.32 years
STANDARD_DEVIATION 17.07 • n=7755 Participants
|
|
Sex: Female, Male
Female
|
2,602 Participants
n=4 Participants
|
1,302 Participants
n=3002 Participants
|
3904 Participants
n=7755 Participants
|
|
Sex: Female, Male
Male
|
2,151 Participants
n=4 Participants
|
1,700 Participants
n=3002 Participants
|
3851 Participants
n=7755 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
4753 Participants
n=4 Participants
|
3002 Participants
n=3002 Participants
|
7755 Participants
n=7755 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
0 Participants
n=4 Participants
|
0 Participants
n=3002 Participants
|
0 Participants
n=7755 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=4 Participants
|
0 Participants
n=3002 Participants
|
0 Participants
n=7755 Participants
|
|
Region of Enrollment
Spain
|
4753 Participants
n=4 Participants
|
3002 Participants
n=3002 Participants
|
7755 Participants
n=7755 Participants
|
|
Education
No education
|
373 Participants
n=4 Participants
|
100 Participants
n=3002 Participants
|
473 Participants
n=7755 Participants
|
|
Education
Less than primary
|
1,001 Participants
n=4 Participants
|
353 Participants
n=3002 Participants
|
1354 Participants
n=7755 Participants
|
|
Education
Primary
|
1,306 Participants
n=4 Participants
|
761 Participants
n=3002 Participants
|
2067 Participants
n=7755 Participants
|
|
Education
Secondary
|
562 Participants
n=4 Participants
|
428 Participants
n=3002 Participants
|
990 Participants
n=7755 Participants
|
|
Education
High School
|
874 Participants
n=4 Participants
|
724 Participants
n=3002 Participants
|
1598 Participants
n=7755 Participants
|
|
Education
University+
|
572 Participants
n=4 Participants
|
460 Participants
n=3002 Participants
|
1032 Participants
n=7755 Participants
|
|
Education
Post graduate degree
|
64 Participants
n=4 Participants
|
175 Participants
n=3002 Participants
|
239 Participants
n=7755 Participants
|
|
Education
missing data
|
1 Participants
n=4 Participants
|
1 Participants
n=3002 Participants
|
2 Participants
n=7755 Participants
|
|
Marital status
Single
|
680 Participants
n=4 Participants
|
495 Participants
n=3002 Participants
|
1175 Participants
n=7755 Participants
|
|
Marital status
Married
|
2,670 Participants
n=4 Participants
|
1,666 Participants
n=3002 Participants
|
4336 Participants
n=7755 Participants
|
|
Marital status
Cohabiting
|
175 Participants
n=4 Participants
|
127 Participants
n=3002 Participants
|
302 Participants
n=7755 Participants
|
|
Marital status
Separated/divorced
|
346 Participants
n=4 Participants
|
306 Participants
n=3002 Participants
|
652 Participants
n=7755 Participants
|
|
Marital status
widowed
|
882 Participants
n=4 Participants
|
408 Participants
n=3002 Participants
|
1290 Participants
n=7755 Participants
|
|
Health Status
|
66.55 units on a scale
STANDARD_DEVIATION 13.11 • n=4 Participants
|
68.95 units on a scale
STANDARD_DEVIATION 19.87 • n=3002 Participants
|
67.75 units on a scale
STANDARD_DEVIATION 16.49 • n=7755 Participants
|
PRIMARY outcome
Timeframe: BaselineMeasure: Health composite total score. Construct: Health status. Final result: A global total score. Range: 0-100. 0 means lower health status.
Outcome measures
| Measure |
Cohort 2011
n=4753 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=3 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Heath Status
|
66.55 score on a scale
Standard Deviation 13.11
|
68.95 score on a scale
Standard Deviation 19.87
|
PRIMARY outcome
Timeframe: BaselineMeasure: World Health Organization's Disability Assessment Schedule-II (WHODAS-II). Construct: Disability. Final result: A global total score. Range: 0-100. 0 means lower disability
Outcome measures
| Measure |
Cohort 2011
n=4 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=3 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Disability
|
11.17 score on a scale
Standard Deviation 17.59
|
9.01 score on a scale
Standard Deviation 18.20
|
PRIMARY outcome
Timeframe: BaselinePopulation: Proxy respondent were not analysed
Abbreviated Version of the Day Reconstruction Method. Construct: Experienced wellbeing. Final Result: The used scale reports two global scores: * Positive Affect total score. Range: 0-100 where 0 means lower positive affect. * Negative Affect total score. Range 0-100 where 0 means lower negative affect.
Outcome measures
| Measure |
Cohort 2011
n=4753 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=3 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Experienced Well-being
Negative Affect
|
0.64 score on a scale
Standard Deviation 0.89
|
0.33 score on a scale
Standard Deviation 0.61
|
|
Experienced Well-being
Positive Affect
|
4.88 score on a scale
Standard Deviation 1.11
|
4.75 score on a scale
Standard Deviation 1.59
|
PRIMARY outcome
Timeframe: BaselinePopulation: Proxy respondent were not analysed
Measure: World Health Organization Quality of Life-Age (WHOQOL-AGE) (Caballero, et al., 2013). Construct: Quality of life. Final Result: A global total score. Range 0-100. 0 means lower quality of life
Outcome measures
| Measure |
Cohort 2011
n=4583 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=2 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Quality of Life (WHOQOL-AGE)
|
72.30 score on a scale
Standard Deviation 14.90
|
76.17 score on a scale
Standard Deviation 15.25
|
SECONDARY outcome
Timeframe: BaselinePopulation: Proxy respondent were not analysed
Measure: The World Health Organization Composite International Diagnostic Interview (CIDI). Depression module (WHO-CIDI, 1990). Construct: Presence of Depression. Final result: Two measures of depression according to Research Diagnostic Criteria. * Presence of 12 month depression. Values (yes/no). * Presence of lifetime depression. Values (yes/no).
Outcome measures
| Measure |
Cohort 2011
n=4583 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=2911 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Number of Participants With Depression
|
510 Participants
|
203 Participants
|
SECONDARY outcome
Timeframe: BaselineMeasure: The World Health Organization Composite International Diagnostic Interview (CIDI). Suicide module (WHO-CIDI, 1990). Construct: Presence of Suicide behavior The instrument reports six measures of suicide behavior. * Presence of 12 month suicide ideation. Values (yes/no) * Presence of 12 month suicide planning. Values (yes/no) * Presence of 12 month suicide attempts. Values (yes/no) * Presence of lifetime suicide ideation. Values (yes/no) * Presence of lifetime suicide planning. Values (yes/no) * Presence of lifetime suicide attempts. Values (yes/no)
Outcome measures
| Measure |
Cohort 2011
n=4753 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=3 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Presence of Suicide Behavior
|
161 Participants
|
75 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: Proxy respondent were not analysed
Measure: The World Health Organization Composite International Diagnostic Interview (CIDI). Anxiety disorders module (WHO-CIDI, 1990). Construct: Presence of anxiety Disorders Final Result: The instrument included in the study reports six measures of anxiety disorders according to Research diagnostic criteria. * Presence of 12 month panic disorder. Values (yes/no) * Presence of 12 month generalized anxiety disorder. Values (yes/no) * Presence of 12 month phobic disorder. Values (yes/no) * Presence of lifetime panic disorder. Values (yes/no) * Presence of lifetime generalized anxiety disorder. Values (yes/no) * Presence of lifetime phobic disorder. Values (yes/no)
Outcome measures
| Measure |
Cohort 2011
n=4583 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=3 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Presence of Anxiety Disorders
|
69 Participants
|
77 Participants
|
SECONDARY outcome
Timeframe: BaselineConstruct: Presence of diabetes Measure: Self-reported information of 12-month presence of diagnosis and/or of treatment for diabetes Values: (Yes/No)
Outcome measures
| Measure |
Cohort 2011
n=4 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=3 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Presence of Diabetes
|
661 Participants
|
353 Participants
|
SECONDARY outcome
Timeframe: BaselineConstruct: Presence of any lung disease Measure: Self-reported information of 12-month presence of diagnosis and/or of treatment for any lung disease Values: (Yes/No)
Outcome measures
| Measure |
Cohort 2011
n=4753 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=3 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Presence of Lung Disease
|
399 Participants
|
152 Participants
|
SECONDARY outcome
Timeframe: BaselineConstruct: Presence of stroke Measure: Self-reported information of 12-month presence of diagnosis and/or of treatment for stroke Values: (Yes/No)
Outcome measures
| Measure |
Cohort 2011
n=4753 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=3 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Presence of Stroke
|
183 Participants
|
82 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: BaselinePopulation: Proxy respondent were not analysed
Construct: Alcohol use Measure: Self-reported information of how many standard drinks per day in last 7 days have been used. Values: four categories of alcohol use: 0= Lifetime abstainers: Participants that have never used alcohol 1. Occasional drinkers: Participants that have ever used alcohol but not in the previous 7 days 2. Non-heavy drinker: Participants did consume alcohol in the last 30 days and in the last 7 days 3. Infrequent heavy drinker: Participants did consume alcohol 1-2 days per week, with 5 or more standard drinks per day in last 7 days for men and 4 or more standard drinks per day in last 7 days for women. 4. Frequent heavy drinkers: Participants did consume alcohol 3 or more days per week with 5 or more standard drinks per day in last 7 days for men and 4 or more standard drinks per day in last 7 days for women.
Outcome measures
| Measure |
Cohort 2011
n=4583 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=2911 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Alcohol Use Information
Lifetime abstainers
|
1,345 Participants
|
871 Participants
|
|
Alcohol Use Information
Occasional drinkers
|
1,424 Participants
|
1,055 Participants
|
|
Alcohol Use Information
Non-heavy drinker
|
1,671 Participants
|
846 Participants
|
|
Alcohol Use Information
Infrequent heavy drinker
|
111 Participants
|
95 Participants
|
|
Alcohol Use Information
Frequent heavy drinker
|
32 Participants
|
38 Participants
|
|
Alcohol Use Information
Missing
|
0 Participants
|
6 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: BaselinePopulation: Proxy respondent were not analysed
Construct: Tobacco use Measure: Self-reported information of how many cigarettes/pipes/tobacco products/ have been used in the last week. Values: Four categories of tobacco use: 0= Never smokers: Participants who have never used tobacco 1. Daily smokers: Participants who have used tobacco last week 2. Non daily smokers: Participants who have ever used tobacco but not in the previous week 3. Former smokers: Participants who smoked in the past (ex smokers)
Outcome measures
| Measure |
Cohort 2011
n=4583 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=2911 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Tobacco Use Information
Never smokers
|
2,339 Participants
|
1,543 Participants
|
|
Tobacco Use Information
Daily smokers
|
1,049 Participants
|
626 Participants
|
|
Tobacco Use Information
Non daily smokers
|
100 Participants
|
52 Participants
|
|
Tobacco Use Information
Former smokers
|
1095 Participants
|
690 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: BaselinePopulation: Proxy respondent were not analysed
Construct: Level of physical activity Scale: Global Physical Activity Questionnaire version 2 (GPAQ v2); It collects information on physical activity participation in three settings (or domains) and sedentary behavior. The responses given by the participants have been converted to Metabolic Equivalent to Task (MET) values. Applying MET values to activity levels allows for calculating total physical activities. Values: Three values of physical activity can be obtained 3=High physical activity 2=Moderate physical activity 1=Low physical activity
Outcome measures
| Measure |
Cohort 2011
n=4583 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=2902 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Level of Physical Activity
high
|
1,464 Participants
|
898 Participants
|
|
Level of Physical Activity
Moderate
|
1,724 Participants
|
1,013 Participants
|
|
Level of Physical Activity
Low
|
1,395 Participants
|
991 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: BaselineConstruct: Social Support Measure: 3-Item Oslo Social Support Scale (OSLO) (Abiola et al., 2013) Result: A global total score, then transformed into a percentile scale. Range: 0-100. Higher scores indicate a higher social support.
Outcome measures
| Measure |
Cohort 2011
n=4753 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=3 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Level of Social Support
|
77.50 score on a scale
Standard Deviation 16.73
|
77.44 score on a scale
Standard Deviation 17.70
|
OTHER_PRE_SPECIFIED outcome
Timeframe: BaselineConstruct: Loneliness Measure: Three-item University of California, Los Angeles (UCLA) Loneliness Scale (Hughes et al, 2004) Result: A total loneliness score, then transformed into a percentile scale. Range: 0-100. Higher scores means higher loneliness
Outcome measures
| Measure |
Cohort 2011
n=4753 Participants
A total of 4753 persons participated at baseline between 2011 and 2012.
|
Cohort 2019
n=3 Participants
3,002 persons participated at this baseline between 2019 and 2021
|
|---|---|---|
|
Intensity of Subjective Perception of Loneliness
|
12.34 score on a scale
Standard Deviation 24.25
|
10.74 score on a scale
Standard Deviation 22.82
|
Adverse Events
Cohort 2011
Cohort 2019
Serious adverse events
| Measure |
Cohort 2011
n=4753 participants at risk
The data comprising the 2011 reference cohort were collected as part of the Collaborative Research on Ageing in Europe (COURAGE in Europe) project between July 2011 and May 2012. It consisted of a representative sample of the Spanish adult population over 50 years of age, with an oversampling of older people and a representative comparison sample of individuals aged 18-49 years. Potential respondents were selected using a stratified, multistage, stratified probability design, by clustered areas without replacement, according to Spanish regions and population size. The primary sampling unit consisted of municipalities. A number of census units (the secondary sampling unit) were chosen from each of them. Age strata were then used to randomly select 10 households within each census unit (the tertiary sampling unit). Finally, a list of household occupants was drawn up, from which one participant was randomly selected following age quotas. Institutionalized persons were not included in the initial interviews. At baseline, 4,753 participants were interviewed, of which 2,528 were interviewed in the second wave (2014-2015), 1,577 in the third wave (2010-2021) and 963 in the fourth wave (2022-2023).
|
Cohort 2019
n=3002 participants at risk
The sample of the 2019 cohort is a new representative refreshment sample from the provinces of Barcelona and Madrid, to compensate for attrition (e.g., deaths, dropouts) from the 2011 cohort. Household selection was also multistage. At the primary sampling unit level, households were defined using predefined routes and an omission factor. Households were assigned to one of two age groups (i.e., household aged 18-49 years or household aged 50 years or older) and interviewers hand-delivered the invitation letter to the selected households. All residents in the eligible age group were invited to participate in the survey. In this first wave, 3 002 participants joined and in 2022 the second selection of participants for the 2019 cohort was conducted, of which 1 037 participants were interviewed.
|
|---|---|---|
|
Vascular disorders
Stroke
|
5.9%
280/4753 • For both cohorts (2011 and 2019), data on adverse events and deaths are collected at the same time, when a new wave is carried out. Specifically for cohort 2011 adverse events have been evaluated 4 times during 12 years (2011-2012, 2014-2015, 2019-2021 and 2022-2023) and for cohort 2019 they have been evaluated 2 times during 4 years (2019-2020 and 2022-2023).
Diverse chronic conditions were assessed through self-reported physician's diagnosis, symptom-based algorithms (e.g., stroke, chronic obstructive lung disease - COPD), and/or measurements to detect undiagnosed cases. This section also included questions on treatments and age of onset
|
2.7%
82/3002 • For both cohorts (2011 and 2019), data on adverse events and deaths are collected at the same time, when a new wave is carried out. Specifically for cohort 2011 adverse events have been evaluated 4 times during 12 years (2011-2012, 2014-2015, 2019-2021 and 2022-2023) and for cohort 2019 they have been evaluated 2 times during 4 years (2019-2020 and 2022-2023).
Diverse chronic conditions were assessed through self-reported physician's diagnosis, symptom-based algorithms (e.g., stroke, chronic obstructive lung disease - COPD), and/or measurements to detect undiagnosed cases. This section also included questions on treatments and age of onset
|
|
Respiratory, thoracic and mediastinal disorders
Lungs problems
|
9.0%
426/4753 • For both cohorts (2011 and 2019), data on adverse events and deaths are collected at the same time, when a new wave is carried out. Specifically for cohort 2011 adverse events have been evaluated 4 times during 12 years (2011-2012, 2014-2015, 2019-2021 and 2022-2023) and for cohort 2019 they have been evaluated 2 times during 4 years (2019-2020 and 2022-2023).
Diverse chronic conditions were assessed through self-reported physician's diagnosis, symptom-based algorithms (e.g., stroke, chronic obstructive lung disease - COPD), and/or measurements to detect undiagnosed cases. This section also included questions on treatments and age of onset
|
5.1%
152/3002 • For both cohorts (2011 and 2019), data on adverse events and deaths are collected at the same time, when a new wave is carried out. Specifically for cohort 2011 adverse events have been evaluated 4 times during 12 years (2011-2012, 2014-2015, 2019-2021 and 2022-2023) and for cohort 2019 they have been evaluated 2 times during 4 years (2019-2020 and 2022-2023).
Diverse chronic conditions were assessed through self-reported physician's diagnosis, symptom-based algorithms (e.g., stroke, chronic obstructive lung disease - COPD), and/or measurements to detect undiagnosed cases. This section also included questions on treatments and age of onset
|
Other adverse events
| Measure |
Cohort 2011
n=4753 participants at risk
The data comprising the 2011 reference cohort were collected as part of the Collaborative Research on Ageing in Europe (COURAGE in Europe) project between July 2011 and May 2012. It consisted of a representative sample of the Spanish adult population over 50 years of age, with an oversampling of older people and a representative comparison sample of individuals aged 18-49 years. Potential respondents were selected using a stratified, multistage, stratified probability design, by clustered areas without replacement, according to Spanish regions and population size. The primary sampling unit consisted of municipalities. A number of census units (the secondary sampling unit) were chosen from each of them. Age strata were then used to randomly select 10 households within each census unit (the tertiary sampling unit). Finally, a list of household occupants was drawn up, from which one participant was randomly selected following age quotas. Institutionalized persons were not included in the initial interviews. At baseline, 4,753 participants were interviewed, of which 2,528 were interviewed in the second wave (2014-2015), 1,577 in the third wave (2010-2021) and 963 in the fourth wave (2022-2023).
|
Cohort 2019
n=3002 participants at risk
The sample of the 2019 cohort is a new representative refreshment sample from the provinces of Barcelona and Madrid, to compensate for attrition (e.g., deaths, dropouts) from the 2011 cohort. Household selection was also multistage. At the primary sampling unit level, households were defined using predefined routes and an omission factor. Households were assigned to one of two age groups (i.e., household aged 18-49 years or household aged 50 years or older) and interviewers hand-delivered the invitation letter to the selected households. All residents in the eligible age group were invited to participate in the survey. In this first wave, 3 002 participants joined and in 2022 the second selection of participants for the 2019 cohort was conducted, of which 1 037 participants were interviewed.
|
|---|---|---|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
17.0%
808/4753 • For both cohorts (2011 and 2019), data on adverse events and deaths are collected at the same time, when a new wave is carried out. Specifically for cohort 2011 adverse events have been evaluated 4 times during 12 years (2011-2012, 2014-2015, 2019-2021 and 2022-2023) and for cohort 2019 they have been evaluated 2 times during 4 years (2019-2020 and 2022-2023).
Diverse chronic conditions were assessed through self-reported physician's diagnosis, symptom-based algorithms (e.g., stroke, chronic obstructive lung disease - COPD), and/or measurements to detect undiagnosed cases. This section also included questions on treatments and age of onset
|
26.4%
794/3002 • For both cohorts (2011 and 2019), data on adverse events and deaths are collected at the same time, when a new wave is carried out. Specifically for cohort 2011 adverse events have been evaluated 4 times during 12 years (2011-2012, 2014-2015, 2019-2021 and 2022-2023) and for cohort 2019 they have been evaluated 2 times during 4 years (2019-2020 and 2022-2023).
Diverse chronic conditions were assessed through self-reported physician's diagnosis, symptom-based algorithms (e.g., stroke, chronic obstructive lung disease - COPD), and/or measurements to detect undiagnosed cases. This section also included questions on treatments and age of onset
|
|
Metabolism and nutrition disorders
Diabetes
|
6.8%
325/4753 • For both cohorts (2011 and 2019), data on adverse events and deaths are collected at the same time, when a new wave is carried out. Specifically for cohort 2011 adverse events have been evaluated 4 times during 12 years (2011-2012, 2014-2015, 2019-2021 and 2022-2023) and for cohort 2019 they have been evaluated 2 times during 4 years (2019-2020 and 2022-2023).
Diverse chronic conditions were assessed through self-reported physician's diagnosis, symptom-based algorithms (e.g., stroke, chronic obstructive lung disease - COPD), and/or measurements to detect undiagnosed cases. This section also included questions on treatments and age of onset
|
11.8%
353/3002 • For both cohorts (2011 and 2019), data on adverse events and deaths are collected at the same time, when a new wave is carried out. Specifically for cohort 2011 adverse events have been evaluated 4 times during 12 years (2011-2012, 2014-2015, 2019-2021 and 2022-2023) and for cohort 2019 they have been evaluated 2 times during 4 years (2019-2020 and 2022-2023).
Diverse chronic conditions were assessed through self-reported physician's diagnosis, symptom-based algorithms (e.g., stroke, chronic obstructive lung disease - COPD), and/or measurements to detect undiagnosed cases. This section also included questions on treatments and age of onset
|
|
Eye disorders
Cataract
|
6.6%
314/4753 • For both cohorts (2011 and 2019), data on adverse events and deaths are collected at the same time, when a new wave is carried out. Specifically for cohort 2011 adverse events have been evaluated 4 times during 12 years (2011-2012, 2014-2015, 2019-2021 and 2022-2023) and for cohort 2019 they have been evaluated 2 times during 4 years (2019-2020 and 2022-2023).
Diverse chronic conditions were assessed through self-reported physician's diagnosis, symptom-based algorithms (e.g., stroke, chronic obstructive lung disease - COPD), and/or measurements to detect undiagnosed cases. This section also included questions on treatments and age of onset
|
10.9%
327/3002 • For both cohorts (2011 and 2019), data on adverse events and deaths are collected at the same time, when a new wave is carried out. Specifically for cohort 2011 adverse events have been evaluated 4 times during 12 years (2011-2012, 2014-2015, 2019-2021 and 2022-2023) and for cohort 2019 they have been evaluated 2 times during 4 years (2019-2020 and 2022-2023).
Diverse chronic conditions were assessed through self-reported physician's diagnosis, symptom-based algorithms (e.g., stroke, chronic obstructive lung disease - COPD), and/or measurements to detect undiagnosed cases. This section also included questions on treatments and age of onset
|
Additional Information
José Luis Ayuso Mateos
Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Madrid, Spain.
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place